KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) FCF Margin (2019 - 2025)

Historic FCF Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to 4.91%.

  • Esperion Therapeutics' FCF Margin rose 638000.0% to 4.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 30.71%, marking a year-over-year decrease of 218800.0%. This contributed to the annual value of 7.21% for FY2024, which is 1092500.0% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' FCF Margin is 4.91%, which was up 638000.0% from 38.14% recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' FCF Margin ranged from a high of 38.94% in Q1 2024 and a low of 1116.42% during Q1 2021
  • In the last 5 years, Esperion Therapeutics' FCF Margin had a median value of 114.9% in 2023 and averaged 193.4%.
  • Data for Esperion Therapeutics' FCF Margin shows a peak YoY increase of 26746100bps (in 2021) and a maximum YoY decrease of -1832300bps (in 2021) over the last 5 years.
  • Over the past 5 years, Esperion Therapeutics' FCF Margin (Quarter) stood at 374.69% in 2021, then skyrocketed by 40bps to 225.7% in 2022, then skyrocketed by 49bps to 114.9% in 2023, then surged by 56bps to 50.57% in 2024, then skyrocketed by 90bps to 4.91% in 2025.
  • Its last three reported values are 4.91% in Q3 2025, 38.14% for Q2 2025, and 34.81% during Q1 2025.